Physician profile
Steven Dilauro
NPI 1629117643
$17,010.49
in general payments reported to CMS, 2019-2025
47 companies · $2,955 in 2025
The $2,955 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,136 · 2020: $1,506 · 2021: $2,551 · 2022: $2,813 · 2023: $2,478 · 2024: $2,571 · 2025: $2,955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,940 · Education: $64.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,939.67 |
| Education | $64.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,976.39 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $2,210.46 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,700.41 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,608.85 | 2019-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $704.31 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $566.84 | 2021-2023 | |
| Celgene Corporation | $555.31 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $482.55 | 2019-2024 | Dificid, Zinplava |
| Intercept Pharmaceuticals, INC. | $482.38 | 2019-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $408.94 | 2020-2023 | Linzess |
| Lilly USA, LLC | $346.48 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $304.05 | 2019-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $301.40 | 2024-2025 | Voquezna |
| Pfizer INC. | $294.91 | 2019-2025 | |
| Madrigal Pharmaceuticals | $248.97 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Dilauro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.